-
Je něco špatně v tomto záznamu ?
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
JW. Eikelboom, J. Bosch, SJ. Connolly, J. Tyrwitt, KAA. Fox, E. Muehlhofer, C. Neumann, C. Tasto, SI. Bangdiwala, R. Diaz, M. Alings, GR. Dagenais, DP. Leong, EM. Lonn, A. Avezum, LS. Piegas, P. Widimsky, AN. Parkhomenko, DL. Bhatt, KRH. Branch,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
PubMed Central
od 2015
ProQuest Central
od 2016-10-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2016-10-01 do Před 1 rokem
PubMed
35383832
DOI
10.1093/ehjcvp/pvac023
Knihovny.cz E-zdroje
- MeSH
- Aspirin MeSH
- cévní mozková příhoda * epidemiologie MeSH
- infarkt myokardu * epidemiologie MeSH
- kojenec MeSH
- kombinovaná farmakoterapie MeSH
- lidé MeSH
- onemocnění periferních arterií * diagnóza farmakoterapie epidemiologie MeSH
- rivaroxaban MeSH
- Check Tag
- kojenec MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
AIMS: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial who were treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily during long-term open-label extension (LTOLE). METHODS AND RESULTS: Of the 27 395 patients enrolled in COMPASS, 12 964 (mean age at baseline 67.2 years) from 455 sites in 32 countries were enrolled in LTOLE and treated with the combination of rivaroxaban and aspirin for a median of 374 additional days (range 1-1191 days). During LTOLE, the incident events per 100 patient years were as follows: for the primary outcome [cardiovascular death, stroke, or myocardial infarction (MI)] 2.35 [95% confidence interval (CI) 2.11-2.61], mortality 1.87 (1.65-2.10), stroke 0.62 (0.50-0.76), and MI 1.02 (0.86-1.19), with CIs that overlapped those seen during the randomized treatment phase with the combination of rivaroxaban and aspirin. The incidence rates for major and minor bleeding were 1.01 (0.86-1.19) and 2.49 (2.24-2.75), compared with 1.67 (1.48-1.87) and 5.11 (95% CI 4.77-5.47), respectively, during the randomized treatment phase with the combination. CONCLUSION: In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals.
ANMCO Research Center Heart Care Foundation Florence Italy
Bayer AG Pharmaceuticals Research and Development Wuppertal Germany
Brigham and Women's Hospital Harvard Medical School Boston MA USA
Catholic University of Korea Department of Medicine Seoul South Korea
Centre for Cardiovascular Science University of Edinburgh Edinburgh UK
College of Medicine University of Philippines Manila Philippines
Department of Cardiology Dupuytren University Hospital and INSERM 1094 Limoges France
Department of Cardiovascular Sciences University Hospitals Leuven Leuven Belgium
Department of Medicine Jagiellonian University Medical College Krakow Poland
Department of Medicine K2 Karolinska Institutet Stockholm Sweden
Department of Oncocardiology Osaka International Cancer Institute Osaka Japan
Dept of Clinical Medicine University of Aalborg Copenhagen Denmark
Division of Medicine Turku University Hospital and University of Turku Turku Finland
Emergency Cardiology Dept National Scientific Center Institute of Cardiology Kyiv Ukraine
Estudios Clínicos Latino América and Instituto Cardiovascular de Rosario Rosaria Argentina
Facultad de Ciencias de la Salud Eugenio Espejo Universidad UTE Quito Ecuador
Faculty of Medicine Universiti Teknologi MARA Selangor Malaysia
Fuwai Hospital CAMS and PUMC Beijing China
Hungarian Cardiovascular Institute Semmelweis University Budapest Hungary
Institut universitaire de cardiologie et de pneumologie de Québec Québec QC Canada
Institute of Cardiovascular and Medical Sciences University of Glasgow Glasgow UK
International Research Center Hospital Alemão Oswaldo Cruz São Paulo Brazil
NUI Galway Department of Medicine Ireland
Research Institute Fundación Oftalmológica de Santander Bucaramanga Bucaramanga Colombia
Research Institute HCor Hospital do Coração São Paulo Brazil
School of Public Health and Preventive Medicine Monash University Melbourne Australia
School of Rehabilitation Science McMaster University Hamilton Canada
Thrombosis Research Institute and University College London London UK
Universidad de La Frontera Division of Cardiology Internal Medicine Department Temuco Chile
Université de Paris and Hôpital Bichat Assistance Publique Hôpitaux de Paris Paris France
University and Emergency Hospital Bucharest Romania
University of Medicine and Pharmacy Carol Davila
University of Washington Medical Centre Division of Cardiology Seattle WA USA
University of Washington SOM Division of Cardiology Department of Medicine Seattle WA USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032270
- 003
- CZ-PrNML
- 005
- 20230131151749.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/ehjcvp/pvac023 $2 doi
- 035 __
- $a (PubMed)35383832
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Eikelboom, John W $u Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton Canada $1 https://orcid.org/0000000341261285
- 245 10
- $a Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial / $c JW. Eikelboom, J. Bosch, SJ. Connolly, J. Tyrwitt, KAA. Fox, E. Muehlhofer, C. Neumann, C. Tasto, SI. Bangdiwala, R. Diaz, M. Alings, GR. Dagenais, DP. Leong, EM. Lonn, A. Avezum, LS. Piegas, P. Widimsky, AN. Parkhomenko, DL. Bhatt, KRH. Branch, JL. Probstfield, P. Lopez-Jaramillo, L. Rydén, N. Pogosova, K. Keltai, M. Keltai, G. Ertl, S. Stoerk, AL. Dans, F. Lanas, Y. Liang, J. Zhu, C. Torp-Pedersen, AP. Maggioni, PJ. Commerford, TJ. Guzik, T. Vanassche, P. Verhamme, M. O'Donnell, AM. Tonkin, JD. Varigos, D. Vinereanu, C. Felix, JH. Kim, KS. Ibrahim, BS. Lewis, KP. Metsarinne, V. Aboyans, PG. Steg, M. Hori, A. Kakkar, SS. Anand, A. Lamy, M. Sharma, S. Yusuf
- 520 9_
- $a AIMS: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) randomized trial who were treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily during long-term open-label extension (LTOLE). METHODS AND RESULTS: Of the 27 395 patients enrolled in COMPASS, 12 964 (mean age at baseline 67.2 years) from 455 sites in 32 countries were enrolled in LTOLE and treated with the combination of rivaroxaban and aspirin for a median of 374 additional days (range 1-1191 days). During LTOLE, the incident events per 100 patient years were as follows: for the primary outcome [cardiovascular death, stroke, or myocardial infarction (MI)] 2.35 [95% confidence interval (CI) 2.11-2.61], mortality 1.87 (1.65-2.10), stroke 0.62 (0.50-0.76), and MI 1.02 (0.86-1.19), with CIs that overlapped those seen during the randomized treatment phase with the combination of rivaroxaban and aspirin. The incidence rates for major and minor bleeding were 1.01 (0.86-1.19) and 2.49 (2.24-2.75), compared with 1.67 (1.48-1.87) and 5.11 (95% CI 4.77-5.47), respectively, during the randomized treatment phase with the combination. CONCLUSION: In patients with chronic CAD and/or PAD, extended combination treatment for a median of 1 year and a maximum of 3 years was associated with incidence rates for efficacy and bleeding that were similar to or lower than those seen during the randomized treatment phase, without any new safety signals.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a Aspirin $7 D001241
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 12
- $a infarkt myokardu $x epidemiologie $7 D009203
- 650 12
- $a onemocnění periferních arterií $x diagnóza $x farmakoterapie $x epidemiologie $7 D058729
- 650 _2
- $a rivaroxaban $7 D000069552
- 650 12
- $a cévní mozková příhoda $x epidemiologie $7 D020521
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Bosch, Jacqueline $u Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton Canada $u School of Rehabilitation Science, McMaster University, Hamilton, Canada
- 700 1_
- $a Connolly, Stuart J $u Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton Canada
- 700 1_
- $a Tyrwitt, Jessica $u Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton Canada
- 700 1_
- $a Fox, Keith A A $u Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
- 700 1_
- $a Muehlhofer, Eva $u Bayer AG Pharmaceuticals, Research & Development, Wuppertal, Germany
- 700 1_
- $a Neumann, Christoph $u Bayer AG Pharmaceuticals, Research & Development, Wuppertal, Germany
- 700 1_
- $a Tasto, Christoph $u Bayer AG Pharmaceuticals, Research & Development, Wuppertal, Germany
- 700 1_
- $a Bangdiwala, Shrikant I $u Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton Canada
- 700 1_
- $a Diaz, Rafael $u Estudios Clínicos Latino América and Instituto Cardiovascular de Rosario, Rosaria, Argentina $1 https://orcid.org/0000000321819579
- 700 1_
- $a Alings, Marco $u Division of Cardiology, Amphia ziekenhuis, Breda, Netherlands and Werkgroep Cardiologische centra Nederland (WCN), Utrecht, the Netherlands $1 https://orcid.org/0000000320904683
- 700 1_
- $a Dagenais, Gilles R $u Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada
- 700 1_
- $a Leong, Darryl P $u Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton Canada
- 700 1_
- $a Lonn, Eva M $u Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton Canada $1 https://orcid.org/0000000201566730
- 700 1_
- $a Avezum, Alvaro $u International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
- 700 1_
- $a Piegas, Leopoldo S $u Research Institute, HCor, Hospital do Coração, São Paulo, Brazil $1 https://orcid.org/000000031021817X
- 700 1_
- $a Widimsky, Petr $u Cardiocenter, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Parkhomenko, Alexander N $u Emergency Cardiology Dept., National Scientific Center Institute of Cardiology, Kyiv, Ukraine
- 700 1_
- $a Bhatt, Deepak L $u Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA $1 https://orcid.org/0000000212786245
- 700 1_
- $a Branch, Kelley R H $u University of Washington Medical Centre, Division of Cardiology, Seattle, WA, USA
- 700 1_
- $a Probstfield, Jeffrey L $u University of Washington SOM, Division of Cardiology/Department of Medicine, Seattle WA, USA
- 700 1_
- $a Lopez-Jaramillo, Patricio $u Research Institute, Fundación Oftalmológica de Santander (FOSCAL)-Bucaramanga, Bucaramanga, Colombia
- 700 1_
- $a Rydén, Lars $u Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Pogosova, Nana $u National Medical Research Center of Cardiology, Ministry of Healthcare of the Russian Federation, Moscow, Russia $1 https://orcid.org/000000024165804X
- 700 1_
- $a Keltai, Katalin $u Hungarian Cardiovascular Institute, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000282949062
- 700 1_
- $a Keltai, Matyas $u Hungarian Cardiovascular Institute, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Ertl, Georg $u Deutsches Zentrum für Herzinsuffizienz, Medizinische Klinik I, Universitätsklinikum Würzburg, Würzburg, Germany
- 700 1_
- $a Stoerk, Stefan $u Deutsches Zentrum für Herzinsuffizienz, Medizinische Klinik I, Universitätsklinikum Würzburg, Würzburg, Germany
- 700 1_
- $a Dans, Antonio L $u College of Medicine, University of Philippines, Manila, Philippines
- 700 1_
- $a Lanas, Fernando $u Universidad de La Frontera, Division of Cardiology, Internal Medicine Department, Temuco, Chile $1 https://orcid.org/0000000335959759
- 700 1_
- $a Liang, Yan $u Fuwai Hospital, CAMS & PUMC, Beijing, China
- 700 1_
- $a Zhu, Jun $u Dept of Clinical Medicine, University of Aalborg, Copenhagen, Denmark $1 https://orcid.org/0000000243095789
- 700 1_
- $a Torp-Pedersen, Christian $u Dept of Clinical Medicine, University of Aalborg, Copenhagen, Denmark
- 700 1_
- $a Maggioni, Aldo P $u ANMCO Research Center, Heart Care Foundation, Florence, Italy $1 https://orcid.org/0000000327646779
- 700 1_
- $a Commerford, Patrick J $u Division of Cardiology, Department of Medicine, Groote Schuur Hospital and the University of Cape Town, Cape Town, South Africa
- 700 1_
- $a Guzik, Tomasz J $u Department of Medicine, Jagiellonian University Medical College Krakow, Poland $u Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
- 700 1_
- $a Vanassche, Thomas $u Department of Cardiovascular Sciences, University Hospitals Leuven, Leuven, Belgium $1 https://orcid.org/0000000274048918
- 700 1_
- $a Verhamme, Peter $u Department of Cardiovascular Sciences, University Hospitals Leuven, Leuven, Belgium $1 https://orcid.org/0000000186982858
- 700 1_
- $a O'Donnell, Martin $u NUI Galway, Department of Medicine, Ireland
- 700 1_
- $a Tonkin, Andrew M $u School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
- 700 1_
- $a Varigos, John D $u School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
- 700 1_
- $a Vinereanu, Dragos $u University of Medicine and Pharmacy Carol Davila; University and Emergency Hospital, Bucharest, Romania
- 700 1_
- $a Felix, Camillo $u Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador
- 700 1_
- $a Kim, Jae-Hyung $u Catholic University of Korea, Department of Medicine, Seoul, South Korea
- 700 1_
- $a Ibrahim, Khairul S $u Faculty of Medicine, Universiti Teknologi MARA, Selangor, Malaysia
- 700 1_
- $a Lewis, Basil S $u Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
- 700 1_
- $a Metsarinne, Kaj P $u Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland
- 700 1_
- $a Aboyans, Victor $u Department of Cardiology, Dupuytren University Hospital & INSERM 1094, Limoges, France
- 700 1_
- $a Steg, Phillippe Gabriel $u Université de Paris, and Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
- 700 1_
- $a Hori, Masatsugu $u Department of Oncocardiology, Osaka International Cancer Institute, Osaka, Japan
- 700 1_
- $a Kakkar, Ajay $u Thrombosis Research Institute and University College London, London, UK $1 https://orcid.org/000000034054606X
- 700 1_
- $a Anand, Sonia S $u Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton Canada
- 700 1_
- $a Lamy, Andre $u Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton Canada
- 700 1_
- $a Sharma, Mukul $u Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton Canada
- 700 1_
- $a Yusuf, Salim $u Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton Canada
- 773 0_
- $w MED00195025 $t European heart journal. Cardiovascular pharmacotherapy $x 2055-6845 $g Roč. 8, č. 8 (2022), s. 786-795
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35383832 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151745 $b ABA008
- 999 __
- $a ok $b bmc $g 1891178 $s 1183605
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 8 $c 8 $d 786-795 $e 2022Dec02 $i 2055-6845 $m European heart journal. Cardiovascular pharmacotherapy $n Eur Heart J Cardiovasc Pharmacother $x MED00195025
- LZP __
- $a Pubmed-20230120
